FindTrial
Sign In

Intraocular injection of Clindamycin and Dexamethazone in the management of Toxoplasma infection of the retina

Intravitreal Clindamycin and Dexamesathzone with or without systemic anti toxoplasmosis in the management of toxoplasma chorio-retinitis

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009443
Enrollment
30
Registered
2017-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Toxoplasma retinitis

Interventions

Intervention1: group I: intravitreal injection of Clindamycin 1 mg/0.1 ml and Dexamethasone 400 µg/0.1ml. Control Intervention1: Intravitreal injection of Clindamycin and Dexamethazone with or withou

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with active toxoplasma chorioretinitis

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
Resolution of active inflammation, Improvement of visual acuityTimepoint: 3 Months—

Secondary

MeasureTime frame
Decreased macular thickness on OCT Drug adverse effectsTimepoint: 3 months—

Countries

Egypt

Contacts

Public ContactAshraf Bori

ophthalmology department, Faculty of medicine, Zagazig university

ashborai@yahoo.com00201065338080

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026